JPRO
  • JPRO
    • About US >
      • Contact Us
  • What We Do
    • Lean Agent, Local Agency Models
    • Initial Matching Support
  • オフィス概要
  • 事業内容
    • 無償マッチングサポート
    • 事例紹介

The Overview of Japan CRO Market ver. 2016

SKU:
$480.00
$480.00
Unavailable
per item

Summary

Clinical Trial Trend

CRO Market

Industry Association

CRO Players

Emerging CRO Players

Struggling Global CROs

Outsourcing Trend in Pharma

Future Prospect

​
  • Twitter
Not Available
The number of clinical trials in Japan has been recovering in the recent years, and pharma have been integrating studies into global studies over time. Also, pharma have outsourced clinical related works to CROs more and more. As a result, the Japanese CRO market has been expanding for the past 10 years, and reached ¥153 billion in 2015. 
The market has been largely occupied by Tier 1 CROs;  EPS, CMIC, Quintiles and Parexel. Recently, Tier 2 companies; A2 and M3, have been emerging quickly with M&A.
As pharmaceutical companies look for size, capability and quality in CROs, the rest of CROs have seen difficulty to survive in this market over time. 
In the near future, the market will concentrate more on Tier 1 & 2. The rest of CROs need to seek M&A and/or alliances with others, to survive in this market. 
​
Powered by Create your own unique website with customizable templates.
  • JPRO
    • About US >
      • Contact Us
  • What We Do
    • Lean Agent, Local Agency Models
    • Initial Matching Support
  • オフィス概要
  • 事業内容
    • 無償マッチングサポート
    • 事例紹介